Search Results - "Gang, A. O."

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group by Gang, A.O., Strøm, C., Pedersen, M., d’Amore, F., Pedersen, L.M., Bukh, A., Pedersen, B.B., Moeller, M.B., Mortensen, L.S., Gadeberg, O.V., Ingeberg, S., Mourits-Andersen, T., Pulczynski, S., Brown, P.d. Nully

“…Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination…”
Get full text

The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT by Vangsted, A J, Klausen, T W, Ruminski, W, Gimsing, P, Andersen, N F, Gang, A O, Abildgaard, N, Knudsen, L M, Nielsen, J L, Gregersen, H, Vogel, U

“…Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations…”
Get full text

COVID-19-associated pancytopenia can be self-limiting and does not necessarily warrant bone marrow biopsy for the purposes of SARS-CoV-2 diagnostics by Hersby, D.S., Do, T.H., Gang, A.O., Nielsen, T.H.

Get full text

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR⁻/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma by Brimnes, M.K, Vangsted, A.J, Knudsen, L.M, Gimsing, P, Gang, A.O, Johnsen, H.E, Svane, I.M

“…Patients with multiple myeloma (MM) suffer from a general impaired immunity comprising deficiencies in humoral responses, T‐cell responses as well as dendritic…”
Get full text

Next Generation Sequencing in routine diagnostics of mature non‐Hodgkin’s lymphomas. A single‐center real‐life data study by Breinholt, M. F., Schejbel, L., Gang, A. O., Nielsen, T. H., Pedersen, L. M., Høgdall, E., Nørgaard, P.

Get full text

5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies by Gang, A O, Frøsig, T M, Brimnes, M K, Lyngaa, R, Treppendahl, M B, Grønbæk, K, Dufva, I H, Straten, P thor, Hadrup, S R

“…Treatment with the demethylating agent 5-Azacytidine leads to prolonged survival for patients with myelodysplastic syndrome, and the demethylation induces…”
Get full text

Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort Study by Maksten, Eva Futtrup, Jakobsen, Lasse Hjort, Kragholm, Kristian Hay, Baech, Joachim, Andersen, Mikkel Porsborg, Madsen, Jakob, Jørgensen, Judit Mészáros, Clausen, Michael Roost, Pedersen, Robert Schou, Dessau-Arp, Andriette, Larsen, Thomas Stauffer, Poulsen, Christian Bjørn, Gang, Anne Ortved, Brown, Peter, Fonager, Kirsten, El-Galaly, Tarec C, Severinsen, Marianne Tang

“…Many patients diagnosed with lymphoma are of working age. Cancer patients are known to have a higher risk of sick leave and disability pension, but this has…”
Get full text

Early infections in patients undergoing high-dose treatment with stem cell support: a comparison of patients with non-Hodgkin lymphoma and multiple myeloma by Gang, A O, Arpi, M, Gang, Uffe J O, Vangsted, A J

“…Infections are life-threatening complications in patients undergoing high-dose chemotherapy with stem cell support (HDT). Knowledge of the infectious pathogens…”
Get more information

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Breinholt, M F, Schejbel, L, Gang, A O, Nielsen, T H, Pedersen, L M, Høgdall, E, Nørgaard, P

Get full text

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up by Ludvigsen Al-Mashhadi, Ahmed, Simonsen, Mikkel Runason Runason, Cheah, Chan Yoon, Amini, Rose-Marie, Arboe, Bente, Cerhan, James R., Chanchiri, Iman, Clausen, Michael Roost, Day, Jonathan, Eyre, Toby A., Gang, Anne Ortved, Ghesquieres, Herve, Habermann, Thomas M., Hawkes, Eliza A, Hwang, Steven R., Jørgensen, Jennifer B, Khurana, Arushi, Maquet, Claire, Layshe, Ng, Opat, Stephen S., Pedersen, Martin Bjerregård, Poulsen, Christian Bjørn, Rampotas, Alexandros, Sima, Andreea, Ekstroem Smedby, Karin, Smeland, Knut, Smyth, Elizabeth, Thanarajasingam, Gita, Trotman, Judith, Xing, Katharine, Østergaard, Simon, Villa, Diego, El-Galaly, Tarec C

“…Introduction: Splenic marginal zone lymphoma (SMZL) is a rare, indolent disease. There is no universally accepted standard therapy and long-term outcome data…”
Get full text

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma: Immune Impairment in Patients with Multiple Myeloma by Brimnes, M. K., Vangsted, A. J., Knudsen, L. M., Gimsing, P., Gang, A. O., Johnsen, H. E., Svane, I. M.

Get full text

Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study by Rask Kragh Jørgensen, Rasmus, Jakobsen, Lasse Hjort, Eloranta, Sandra, Smedby, Karin E, Pedersen, Robert Schou, Jørgensen, Judit M, Clausen, Michael Roost, Brown, Peter, Gang, Anne Ortved, Gade, Inger-Lise, Larsen, Thomas Stauffer, Jerkeman, Mats, El-Galaly, Tarec Christoffer

“…Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world…”
Get full text

A Real-World Data-Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B-Cell Lymphoma Patients by Jelicic, Jelena, Juul-Jensen, Karen, Bukumiric, Zoran, Runason Simonsen, Mikkel, Roost Clausen, Michael, Ludvigsen Al-Mashhadi, Ahmed, Schou Pedersen, Robert, Bjørn Poulsen, Christian, Ortved Gang, Anne, Brown, Peter, El-Galaly, Tarec Christoffer, Stauffer Larsen, Thomas

“…Recent front-line clinical trials used the International Prognostic Index (IPI) to identify trial-eligible patients with newly diagnosed diffuse large B-cell…”
Get full text

Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study by Baech, Joachim, Severinsen, Marianne Tang, Øvlisen, Andreas Kiesbye, Frederiksen, Henrik, Vestergaard, Peter, Torp-Pedersen, Christian, Jørgensen, Judit M., Clausen, Michael Roost, Poulsen, Christian Bjørn, Brown, Peter de Nully, Ortved Gang, Anne, Pedersen, Robert Schou, Ekstroem Smedby, Karin, Eloranta, Sandra, Jakobsen, Lasse H., El-Galaly, Tarec Christoffer

“…Introduction Prednisolone has important potential side-effects, one of which is steroid-induced diabetes mellitus (DM). Due to the exposure to a high…”
Get full text

The polymorphism IL-1[beta] T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT by Vangsted, A J, Klausen, T W, Ruminski, W, Gimsing, P, Andersen, N F, Gang, A O, Abildgaard, N, Knudsen, L M, Nielsen, J L, Gregersen, H, Vogel, U

“…Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations…”
Get full text

Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark by Jakobsen, Lasse Hjort, Øvlisen, Andreas Kiesbye, Severinsen, Marianne Tang, Bæch, Joachim, Kragholm, Kristian Hay, Glimelius, Ingrid, Gang, Anne Ortved, Jørgensen, Judit Mészáros, Frederiksen, Henrik, Poulsen, Christian Bjørn, Clausen, Michael Roost, Pedersen, Per Trøllund, Pedersen, Robert Schou, Torp-Pedersen, Christian, Eloranta, Sandra, El-Galaly, Tarec Christoffer

“…For most patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), R-CHOP immunochemotherapy leads to complete remission and 60–70% of patients…”
Get full text

Frequency and clinical implications of SOX11 expression in Burkitt lymphoma by Wästerlid, Tove, Nordström, Lena, Freiburghaus, Catja, Pedersen, Mette, Nørgaard, Peter, Gang, Anne O., Brown, Peter, Dictor, Michael, Jerkeman, Mats, Ek, Sara

Get full text

Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy by Baech, Joachim, Severinsen, Marianne Tang, Øvlisen, Andreas K., Frederiksen, Henrik, Vestergaard, Peter, Torp-Pedersen, Christian, Jørgensen, Judit, Clausen, Michael Roost, Poulsen, Christian B., Brown, Peter, Gang, Anne Ortved, Pedersen, Robert Schou, Ekström Smedby, Karin, Eloranta, Sandra, Jakobsen, Lasse Hjort, El-Galaly, Tarec Christoffer

“…First-line treatments for lymphomas often include high doses of prednisolone, but the risks of new-onset diabetes mellitus (DM) or worsening of preexisting DM…”
Get full text

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group by Gang, A O, Strøm, C, Pedersen, M, d'Amore, F, Pedersen, L M, Bukh, A, Pedersen, B B, Moeller, M B, Mortensen, L S, Gadeberg, O V, Ingeberg, S, Mourits-Andersen, T, Pulczynski, S, Brown, P D Nully

“…Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination…”
Get full text

BMI‐1 protein expression as a negative independent prognostic factor in DLBCL by Pedersen, M.Ø., Espersen, M.L., Gang, A.O., Breinholt, M.F., Knudsen, H., Nielsen, S.L., Høgdall, E., Nørgaard, P.

Get full text